• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Discontinuation of tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia - You can do this at home if you read the instructions.慢性粒细胞白血病患者停用酪氨酸激酶抑制剂——如果您阅读说明书，您可以在家自行操作。
Haematologica. 2019 Aug;104(8):1508-1511. doi: 10.3324/haematol.2019.222216.
2
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.慢性粒细胞白血病中的新型酪氨酸激酶抑制剂
Curr Opin Oncol. 2006 Nov;18(6):578-83. doi: 10.1097/01.cco.0000245314.97638.d3.
3
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼：一种用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的酪氨酸激酶抑制剂。
Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
4
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.观察性研究：意大利临床实践中停止使用酪氨酸激酶抑制剂的慢性髓性白血病患者。
Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.
5
BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.用于治疗慢性粒细胞白血病的BCR-ABL1酪氨酸激酶抑制剂
J Oncol Pharm Pract. 2018 Sep;24(6):433-452. doi: 10.1177/1078155217710553. Epub 2017 Jun 4.
6
[Chronic myelogenous leukemia: diagnosis and treatment].[慢性粒细胞白血病：诊断与治疗]
Orv Hetil. 2016 Sep;157(37):1459-68. doi: 10.1556/650.2016.30521.
7
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.慢性粒细胞白血病的分子诊断与监测：BCR-Abl及其他
J BUON. 2009 Oct-Dec;14(4):565-73.
8
Chronic myelogenous leukemia (CML): resistance to tyrosine kinase inhibitors.慢性粒细胞白血病（CML）：对酪氨酸激酶抑制剂的耐药性。
Ann Oncol. 2006 Sep;17 Suppl 10:x274-9. doi: 10.1093/annonc/mdl273.
9
Tyrosine kinase inhibitors for chronic myelogenous leukemia.
N Engl J Med. 2007 Oct 11;357(15):1557; author reply 1557-8.
10
Treating chronic myeloid leukemia in the era of tyrosine kinase inhibitors.酪氨酸激酶抑制剂时代的慢性髓性白血病治疗
Acta Haematol. 2013;130(3):192-5. doi: 10.1159/000351957. Epub 2013 Jun 13.

本文引用的文献

1
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.观察性研究：意大利临床实践中停止使用酪氨酸激酶抑制剂的慢性髓性白血病患者。
Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.
2
Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data.减少酪氨酸激酶抑制剂剂量预计与标准剂量在慢性髓性白血病中同样有效：基于 III 期试验数据的模拟研究。
Haematologica. 2018 Nov;103(11):1825-1834. doi: 10.3324/haematol.2018.194522. Epub 2018 Jun 28.
3
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.酪氨酸激酶抑制剂治疗慢性髓性白血病的停药研究（EURO-SKI）：一项前瞻性、多中心、非随机、试验的预先指定的中期分析。
Lancet Oncol. 2018 Jun;19(6):747-757. doi: 10.1016/S1470-2045(18)30192-X. Epub 2018 May 4.
4
The evolution of dasatinib dosage over the years and its relevance to other anticancer medications.达沙替尼多年来的剂量演变及其与其他抗癌药物的相关性。
Cancer. 2018 Jul 1;124(13):2687-2689. doi: 10.1002/cncr.31516. Epub 2018 May 3.
5
Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.达沙替尼（每日 50 毫克）低剂量作为新诊断的慢性期慢性髓性白血病一线治疗的早期结果。
Cancer. 2018 Jul 1;124(13):2740-2747. doi: 10.1002/cncr.31357. Epub 2018 May 3.
6
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.伊马替尼作为慢性粒细胞白血病一线治疗的评估：随机CML研究IV的10年生存结果及非CML决定因素的影响
Leukemia. 2017 Nov;31(11):2398-2406. doi: 10.1038/leu.2017.253. Epub 2017 Aug 14.
7
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.慢性髓性白血病患者在主要分子反应稳定时酪氨酸激酶抑制剂剂量的降阶梯治疗（DESTINY）：一项非随机2期试验的中期分析
Lancet Haematol. 2017 Jul;4(7):e310-e316. doi: 10.1016/S2352-3026(17)30066-2. Epub 2017 May 26.
8
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.自然杀伤细胞计数与伊马替尼停药后慢性髓性白血病分子无复发生存相关：IMMUNOSTIM 研究。
Haematologica. 2017 Aug;102(8):1368-1377. doi: 10.3324/haematol.2017.165001. Epub 2017 May 18.
9
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.伊马替尼治疗慢性髓性白血病的长期疗效
N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.
10
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.法国停止伊马替尼（STIM1）研究的慢性髓性白血病患者的长期随访。
J Clin Oncol. 2017 Jan 20;35(3):298-305. doi: 10.1200/JCO.2016.68.2914. Epub 2016 Oct 31.

Discontinuation of tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia - You can do this at home if you read the instructions.

作者信息

Schiffer Charles A

机构信息

Joseph Dresner Chair for Hematologic Malignancies, Departments of Oncology and Medicine, Wayne State University School of Medicine, Karmanos Cancer Institute, Detroit, MI, USA.

出版信息

Haematologica. 2019 Aug;104(8):1508-1511. doi: 10.3324/haematol.2019.222216.

DOI:10.3324/haematol.2019.222216
PMID:31366463
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6669156/
Abstract
摘要